1 Banerjee C, Turan TN. Large Artery Atherosclerosis: Extracranial and Intracranial. Semin Neurol. 2017; 37(3):307-15. DOI: 10.1055/s-0037-1603588.
2 Shakur SF, Hrbac T, Alaraj A, Du X, Aletich VA, Charbel FT, et al. Effects of extracranial carotid stenosis on intracranial blood flow. Stroke. 2014; 45(11): 3427-9. DOI: 10.1161/STROKEAHA.114.006622.
3 Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart Disease and Stroke Statistics—2016 Update: A report from the American Heart Association. Circulation. 2016; 133(4):e38–360. DOI: 10.1161/CIR.0000000000000350.
4 Xu J,Liu L,Wang Y,Zhao X, Wang C, Wang A, et al. TOAST subtypes:its influence upon doctors' decisions of antihypertensive prescription at discharge for ischemic stroke patients. Patient Prefer Adherence. 2012; 6:911-4. DOI: 10.2147/PPA.S38565.
5 Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, et al. Editor's Choice - Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018; 55(1):3-81. DOI: 10.1016/j.ejvs.2017.06.021.
6 Chen DW, Zheng J, Shi J, Yin YW, Song C, Yang F, et al..Assessment of the Cerebral Hemodynamic Benefits of Carotid Artery Stenting for Patients with Preoperative Hemodynamic Impairment Using Cerebral Single Photon Emission Computed Tomography (SPECT) and Carbon Dioxide Inhalation. Med Sci Monit. 2018; 24:5398-404. DOI: 10.12659/MSM.909401.
7 Nishijima Y, Akamatsu Y, Weinstein PR, Liu J. Collaterals: Implications in cerebral ischemic diseases and therapeutic interventions. Brain Res. 2015; 1623:18-29. DOI: 10.1016/j.brainres.2015.03.006.
8 Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019; 50(12):e344-e418. DOI: 10.1161/STR.0000000000000211.
9 Wang S, Ma F, Huang L, Zhang Y, Peng Y, Xing C, et al. Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke. CNS Neurol Disord Drug Targets. 2018; 17(5):338-47. DOI: 10.2174/1871527317666180612125843.
10 Xu ZQ, Zhou Y, Shao BZ, Zhang JJ, Liu C. A Systematic Review of Neuroprotective Efficacy and Safety of DL-3-N-Butylphthalide in Ischemic Stroke. Am J Chin Med. 2019; 47(3):507-25. DOI: 10.1142/S0192415X19500265.
11 Xiong Z, Lu W, Zhu L, Zeng L, Shi C, Jing Z, et al. Dl-3-n-Butylphthalide Treatment Enhances Hemodynamics and Ameliorates Memory Deficits in Rats with Chronic Cerebral Hypoperfusion. Front Aging Neurosci. 2017; 9:238. DOI: 10.3389/fnagi.2017.00238.
12 Zhang L, Lü L, Chan WM, Huang Y, Wai MS, Yew DT. Effects of DL-3-n-butylphthalide on vascular dementia and angiogenesis. Neurochem Res. 2012; 37(5):911-9. DOI: 10.1007/s11064-011-0663-3.
13 Han QY, Zhang H, Zhang X, He DS, Wang SW, Cao X, et al. dl-3-n-butylphthalide preserves white matter integrity and alleviates cognitive impairment in mice with chronic cerebral hypoperfusion. CNS Neurosci Ther. 2019; 25(9):1042-53. DOI: 10.1111/cns.13189.
14 Liu CL, Liao SJ, Zeng JS, Lin JW, Li CX, Xie LC, et al. dl-3n-butylphthalide prevents stroke via improvement of cerebral microvessels in RHRSP. J Neurol Sci. 2007; 260(1-2):106-13.DOI:10.1016/j.jns.2007.04.025.
15 Chinese Society of Neurology, Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. Chin.J.Neurol. 2018; 51(9):666-82. DOI:10.3760/ema.j.issn.1006-7876.2010.02022.
16 Kim HJ, Kim TW, Ryu SY, Yang PS, Kwon MJ, Kim JC, et al. Acetazolamide-challenged perfusion magnetic resonance imaging for assessment of cerebrovascular reserve capacity in patients with symptomatic middle cerebral artery stenosis: comparison with technetium-99m-hexamethylpropyleneamine oxime single-photon emission computed tomography. Clin Imaging. 2011; 35(6):413-20. DOI: 10.1016/j.clinimag.2011.03.001.
17 CHENG Pei-li, SHI Jin, ZHANG Wei-qing, ZHENG Jin, ZHANG Ying-qian, Lu Qiang, et al. Change of cerebral perfusion parameters in patients with middle cerebral artery stenosis during a short-term follow-up time. Chin J Geriatr Heart BrainVessel Dis. 2017; 19(2):121-5. DOI: 10.3969/j.issn.1009-0126.2017.02.003.
18 Jia J, Wei C, Liang J, Zhou A, Zuo X, Song H, et al. The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial. Alzheimers Dement. 2016; 12(2):89-99. DOI: 10.1016/j.jalz.2015.04.010.
19 Li Z, Lu J, Ma L, Wu C, Xu Z, Chen X, et al. dl-3-n-butylphthalide for alleviation of neurological deficit after combined extracranial-intracranial revascularization for moyamoya disease: a propensity score-matched analysis. J Neurosurg. 2019; 15:1-13. DOI: 10.3171/2018.10. JNS182152.
20 Chong ZZ, Feng YP. dl-3-n-butylphthalide improves regional cerebral blood flow after experimental subarachnoid hemorrhage in rats. Zhongguo Yao Li Xue Bao. 1999; 20(6):509-12.
21 Spence JD, Naylor AR. Endarterectomy, Stenting, or Neither for Asymptomatic Carotid-Artery Stenosis. N Engl J Med. 2016; 374(11):1087-8. DOI: 10.1056/NEJMe1600123.
22 Ginsberg MD. The cerebral collateral circulation: Relevance to pathophysiology and treatment of stroke.Neuropharmacology. 2018; 134(Pt B):280-92. DOI: 10.1016/j.neuropharm.2017.08.003.
23 Liu J, Wang Y, Akamatsu Y, Lee CC, Stetler RA, Lawton MT, et al. Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials. Prog Neurobiol. 2014; 115:138-56. DOI: 10.1016/j.pneurobio.2013.11.004.
24 Wu Yu-Fu, Liu Xiao-Hong, Guo Wei-Cheng, Zhao Jie, Wang Hao-Ran, He Fei-Fei. Effect. Observation of Butylphthalide Injection in Treating Acute Anterior Circulation Infarction. Chin J Stroke. 2017; 12(12):1111-4. DOI: 10.3969/j.issn.1673-5765.2017.12.008
25 Liao SJ, Lin JW, Pei Z, Liu CL, Zeng JS, Huang RX. Enhanced angiogenesis with dl-3n-butylphthalide treatment after focal cerebral ischemia in RHRSP. Brain Res. 2009; 1289:69-78. DOI: 10.1016/j.brainres.2009.06.018.
26 Zhou PT, Wang LP, Qu MJ, Shen H, Zheng HR, Deng LD, et al. Dl-3-N-butylphthalide promotes angiogenesis and upregulates sonic hedgehog expression after cerebral ischemia in rats. CNS Neurosci Ther. 2019; 25(6):748-58. DOI:10.1111/cns.13104.
27 Jiang Y, Sun L, Xuan X, Wang J. Impacts of N-Butylphthalide on expression of growth factors in rats with focal cerebral ischemia. Bosn J Basic Med Sci. 2016; 16(2):102-7. DOI: 10.17305/bjbms.2016.560.
28 Li W, Wei D, Xie X, Liang J, Song K, Huang L. Dl-3-n-Butylphthalide regulates the Ang-1/Ang-2/Tie-2 signaling axis to promote neovascularization in chronic cerebral hypoperfusion. Biomed Pharmacother. 2019; 113:108757. DOI: 10.1016/j.biopha.2019.108757.
29 Lu XL, Luo D, Yao XL, Wang GL, Liu ZY, Li ZX, et al. dl-3n-Butylphthalide promotes angiogenesis via the extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase/Akt-endothelial nitric oxide synthase signaling pathways. J Cardiovasc Pharmacol. 2012; 59(4):352-62. DOI: 10.1097/ FJC.0b013e3182443e74.